GlobeNewswire Inc | Apr 1, 2021 07:05AM EDT

April 01, 2021

LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

-- Virtual Guggenheim Healthcare Talks2021 Genomic Medicines & Rare Disease, April 1, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Thursday, April 1.Matt Kapusta, chief executive officer, will participate on a panel discussion entitled, The Low-Hanging Fruit in Gene Therapy Might Be Hard to Reach Challenges for Hemophilia A and B on Thursday, April 1 from 10:00 to 10:50 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. Ricardo Dolmetsch, Ph.D., president of research and development, will participate in a panel discussion entitled, An Idea Whose Time has Come Disease Modifying Therapies for Huntingtons Disease later the same day from 3:00 to 3:50 p.m. ET. -- Wells Fargo Corporate Access Days, April 6-8, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, April 6. -- Professional Patient Advocates in Life Sciences, April 13, 2021Daniel Leonard, senior director of global patient advocacy, will participate on a virtual panel discussion entitled, Building an Internal Patient Advocacy & HR Relationship Series Part 1: Journey to Patient Advocacy starting at 2:00 p.m. ET on Tuesday, April 13.

-- 20th Annual Needham Virtual Healthcare Conference, April 12 - 15, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Thursday, April 15.A company presentation with Matt Kapusta will take place the same day from 3:45 to 4:25 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- Chardan 5th Annual Genetic Medicines Manufacturing Summit, April 26 - 27, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings on Tuesday, April 27.A fireside chat with Matt Kapusta will take place the same day from 1:45 to 2:25 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- Kempen Life Sciences Conference 2021 Thematic Virtual Series Cell, Gene & RNA based companies, April 28, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings on Wednesday, April 28. -- CHDIs 16th Annual Huntingtons Disease Therapeutics Conference, April 27-29, 2021David Cooper, M.D., vice president of clinical research CNS, will present in the clinical stage interventional programs session on Thursday, April 29 between 10:00 a.m. and 12:30 p.m. ET. His presentation is entitled, Updates on HD-GeneTRX-1: A Phase 1-2 Clinical Trial of CNS-Administered Gene Therapy (AMT-130) for Early-Stage HD. Following the pre-recorded presentation, Dr. Cooper will be available for live Q&A. Astrid Valles-Sanchez, Ph.D., senior scientist at uniQure, will have a poster presentation entitled, Lowering the Pathogenic Exon1 HTT Fragment by AAV5-miHTT Gene Therapy, during the conference dates. -- World Orphan Drug Congress, April 28, 2021Nick Li, Ph.D., M.B.A., senior director, global/US market access lead, will participate on a panel entitled Pricing & Reimbursement for Rare Diseases in the United States starting at 3:00 p.m. ET on Wednesday, April 28.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

uniQure Contacts:

FOR INVESTORS: FOR MEDIA: Maria E. Cantor Chiara Russo Tom MaloneDirect: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com